We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Drugs to treat cancer and type 2 diabetes are among ...

Detailed results from Novo's trial testing the higher dose of Wegovy, which contains the active ingredient semaglutide, are expected to be presented at a scientific conference in 2025, according ...

Semaglutide, the popular drug sold by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss, is among a group of widely used medicines selected by the U.S. government for the next round ...

The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of medicines containing semaglutide following concerns regarding an increased risk of ...

Semaglutide, the popular drug sold by Novo Nordisk as Ozempic for diabetes and Wegovy for weight loss, is among a group of widely used medicines selected by the U.S. government for the next round of ...

GetSimpli Oral Semaglutide offers a promising solution for those looking to enhance their overall well-being, manage their weight, and improve metabolic health. As an innovative sublingual tablet ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

A first randomized clinical trial shows that semaglutide use in type 1 diabetes is associated with improved glucose management, weight loss and lower insulin requirements. Semaglutide (known by its ...

If you’ve recently stopped taking semaglutide—commonly known by brand names like Ozempic or Wegovy—you may be wondering how to transition back to normal while maintaining your health and weight.

Researchers have established that the application of once-weekly semaglutide in patients with type 2 diabetes (T2D) increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION). A ...

A July 2024 study published in JAMA Ophthalmology found that semaglutide, the active ingredient in Ozempic and Wegovy, was linked to a higher risk of a rare eye condition known as "eye stroke," or non ...